Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?

Clinical Therapeutics

Volumn 37, Issue 9, 2015, Pages 2130-2134

  Harmatz, Paul ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

elosulfase alfa; enzyme replacement therapy; immunogenicity; Key words antidrug antibody; Morquio A syndrome; mucopolysaccharidosis

Indexed keywords

ELOSULFASE ALFA; GALNS PROTEIN, HUMAN; N ACETYLGALACTOSAMINE 4 SULFATASE; NEUTRALIZING ANTIBODY;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; HUMAN; IMMUNOGENICITY; LONG TERM CARE; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSIS; TREATMENT RESPONSE; IMMUNOLOGY; MUCOPOLYSACCHARIDOSIS IV;

ANTIBODIES, NEUTRALIZING; CHONDROITINSULFATASES; ENZYME REPLACEMENT THERAPY; HUMANS; MUCOPOLYSACCHARIDOSIS IV;

EID: 84941168282     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.06.004     Document Type: Article

References (35)

1. F.M. Platt, B. Boland, and A.C. van der Spoel The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction J Cell Biol 199 2012 723 734
2. J.E. Wraith Mucopolysaccharidoses and mucolipidoses Handb Clin Neurol 113 2013 1723 1726
3. A.S. Thomas, and D.A. Hughes Fabry disease Pediatr Endocrinol Rev 12 Suppl 1 2013 88 101
4. A. Dorfman, B. Arbogast, and R. Matalon The enzymic defects in Morquio and Maroteaux-Lamy syndrome Adv Exp Med Biol 68 1976 261 276
5. J. Glössl, and H. Kresse Impaired degradation of keratan sulphate by Morquio A fibroblasts Biochem J 203 1982 335 338
6. C.J. Hendriksz, M. Al-Jawad, K.L. Berger, and et al. Clinical overview and treatment options for nonskeletal manifestations of mucopolysaccharidosis type IV A J Inherit Metab Dis 36 2013 309 322
7. R. Giugliani, P. Harmatz, and J.E. Wraith Management guidelines for mucopolysaccharidosis VI Pediatrics 120 2007 405 418
8. C.J. Hendriksz, C. Lavery, M. Coker, and et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey Orphanet J Rare Dis 9 2014 32
9. P. Harmatz, K.E. Mengel, R. Giuligani, and et al. The Morquio A Clinical Assessment Program: baselines results illustrating progressive, multisystemic clinical impairments in Morquio A subjects Mol Genet Metab 109 2013 54 61
10. C.J. Hendriksz, R. Giugliani, P. Harmatz, and et al. Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial Mol Genet Metab 114 2015 178 185
11. VIMIZIM® US Prescribing Information, BioMarin Pharmaceutical Inc., Novato, CA, 2014. www.vimizim.com.
12. C.J. Hendriksz, B. Burton, T.R. Fleming, and et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study J Inherit Metab Dis 37 2014 979 990
13. B. Schweighardt, T. Tompkins, K. Lau, and et al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial Clin Ther 37 2015 1012 1021
14. th International Congress of Inborn Errors of Metabolism 2013
15. A.M. Montaño, S. Tomatsu, G.S. Gottesman, and et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease J Inherit Metab Dis 30 2007 165 174
16. N. Chirmule, V. Jawa, and B. Meibohn Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy AAPS J 14 2012 296 302
17. S.G. Banugaria, S.N. Prater, Y.K. Ng, and et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease Genet Med 13 2011 729 736
18. S.G. Banugaria, S.N. Prater, T.T. Patel, and et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT PLoS One 8 2013 e67052
19. C. Van Gelder, M. Kroos, L. Ozkan, and et al. Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age BMC Musculoskelet Disord 14 suppl 2 2013 P18
20. P.S. Kishnani, P.C. Goldenberg, S.L. DeArmey, and et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Mol Genet Metab 99 2010 26 33
21. J.M. De Vries, N.A. van der Beek, M.A. Kroos, and et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa Mol Genet Metab 101 2010 338 345
22. M.A. Abbott, S.N. Prater, S.G. Banugaria, and et al. Atypical immunologic response in a patient with CRIM-negative Pompe disease Mol Genet Metab 104 4 2011 583 586
23. L.P. Cousens, F. Mingozzi, S. van de Marel, and et al. Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease Hum Vaccin Immunother 8 2012 1459 1464
24. W.R. Wilcox, G.E. Linthorst, D.P. Germain, and et al. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry Mol Genet Metab 105 2012 443 449
25. A.J. Barbier, DAH Bielefeld, M. Whiteman, and et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase Mol Gen Metab 110 2013 303 310
26. D.S. Bali, J.L. Goldstein, S. Banugaria, and et al. Predicting cross reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience Am J Med Genet C Semin Med Genet 160 2012 40 49
27. S. Tomatsu, A. Montano, T. Nishioka, and et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A) Human Mutat 26 2005 500 512
28. M. Furujo, T. Kubo, M. Kosuga, and T. Okuyama Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI Mol Genet Metab 104 2011 597 602
29. J. McGill, A. Inwood, D. Coman, and et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study Clin Genet 77 2010 492 498
30. Y. Qi, D.G. Musson, B. Schweighardt, and et al. Pharmacokinetic and pharmacodynamics evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome Clin Pharmacokinet 53 2014 1137 1147
31. E. Jameson, S. Jones, and J.E. Wraith Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I Cochrane Database Syst Rev 2013 11 CD009354
32. M.M. Brands, M. Hoogeven-Westerveld, M.A. Kroos, and et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase Orphanet J Rare Dis 8 2013 51
33. B. Benichou, S. Goyal, C. Sung, and et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease Mol Genet Metab 96 2009 4 12
34. S.M. Rombach, J.M. Aerts, B.J. Poorthuis, and et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome PLoS One 7 2012 e47805
35. P.B. Deegan Fabry disease, enzyme replacement therapy and the significance of antibody responses J Inherit Metab Dis 35 2012 227 243